tbuckley/cabot-search huggingface dataset:
Hemodynamic effects of atrial pacing and prenalterol infusion in patients taking beta-adrenergic blocking drugs.
Authors: M F Shiu, M A Ireland, W A Littler
Journal: Circulation (1981)

Prenalterol, a beta-adrenergic agonist, was given to nine patients with angiographically proved coronary artery disease. Subjects were studied during chronic beta-adrenergic blockade. The adequacy of blockade was assessed by the exercise heart rate response and by plasma concentrations of blocking agents. After incremental doses of 2.5 mg, 5.0 mg and 7.5 mg of prenalterol, heart rate was increased by 20%, 24% and 38%, respectively, and left ventricular dP/dt max by 55%, 73% and 61%, respectively. Systolic and diastolic blood pressures did not change significantly; pulmonary artery wedge pressure fell from 10 +/- 0.5 mm Hg to 7.1 +/- 0.9 and 6.7 +/- 0.7 mm Hg after 2.5 mg and 5.0 mg, respectively (p less than 0.01 for both). The net inotropic response to prenalterol was assessed, independent of the chronotropic response, using incremental atrial pacing before and after drug infusion. At identical heart rates, left ventricular dP/dt max increased by 40%, 49% and 48% after 2.5 mg, 5.0 mg and 7.5 mg, respectively. Left ventricular cineangiography before and after infusion showed an increase in ejection fraction from 0.73 +/- 0.02 to 0.83 +/- 0.03 (p less than 0.001). Plasma prenalterol concentration estimations demonstrated a clear, dose-related inotropic response, the level of response in each patient being largely determined by the degree of beta-adrenergic blockade at the time of the study.
Controversial Chelator Approved
Authors: Bridget M. Kuehn
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical editors' trial amnesty
Authors: Richard Tiner
Journal: The Lancet (1997)

Clearly the pharmaceutical industry is one of your target groups in Richard Horton's Sept 13 commentary1Horton R Medical editors' trial amnesty.Lancet. 1997; 350: 756Summary Full Text Full Text PDF PubMed Scopus (37) Google Scholar on the medical editors' trial amnesty. Unfortunately, the word amnesty implies guilt and the Association of the British Pharmaceutical Industry (ABPI) would wish to point out that many trials sponsored by the pharmaceutical industry are put forward for publication but are rejected. This decision leaves the company with three choices: first, to continue to try and get the trial published in another journal; second, to produce its own supplement and publish the trial itself; and third, not to reach publication but to refer to the trial as data on file. Supplements published by a company are often criticised simply because they are self-published. If data on file is referred to in a promotional leaflet, then this information has to be provided to anyone who requests it, which brings it into the public domain. The ABPI guidelines on good clinical practice in clinical trials recommend that a publication policy should be agreed between the investigator and the sponsor before a trial begins. All trials involved in a licensing application have to be reported to the regulatory authority dealing with the application, and some of this information will be available through the voluntary Extended Patient Information Document. Although we accept that there is a need for the pharmaceutical industry to continue to review its publication policy, it is also important that trials submitted for publication should reach the public domain in some form or another.
Predictors of intimal hyperplasia accumulation within Palmaz-Schatz stents: a serial quantitative angiographic and intravascular ultrasound study
Authors: R. Hoffman, G.S. Mintz, R. Mehran, K.M. Kent, A.D. Pichard, L.F. Satler, B. Otjaca, M. Ezibe, J.J. Popma, M.B. Leon
Journal: Journal of the American College of Cardiology (1998)
Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial
Authors: P. Denig, J. Schuling, F. Haaijer-Ruskamp, J. Voorham
Journal: BMJ (2014)

Objective To assess the effects of a patient oriented decision aid for prioritising treatment goals in diabetes compared with usual care on patient empowerment and treatment decisions. Design Pragmatic randomised controlled trial. Setting 18 general practices in the north of the Netherlands. Participants 344 patients with type 2 diabetes aged ≤65 years at the time of diagnosis and managed in primary care between April 2011 and August 2012: 225 were allocated to the intervention group and 119 to the usual care group. Intervention The intervention comprised a decision aid for people with diabetes, with individually tailored risk information and treatment options for multiple risk factors. The aid was intended to empower patients to prioritise between clinical domains and to support treatment decisions. It was offered to participants before a regular diabetes check-up and to their healthcare provider during the consultation. Four different formats of the decision aid were included for additional explorative analyses. Main outcome measures The primary outcome was the effects on patient empowerment for setting and achieving goals. The secondary outcomes were changes in the prescribing of drugs to regulate glucose, blood pressure, lipids, and albuminuria. Data were collected through structured questionnaires and automated data extraction from electronic health records during six months before and after the intervention. Results Of all intervention participants, 103 (46%) reported to have received the basic elements of the intervention. For the primary outcome analysis, 199 intervention and 107 control patients with sufficient baseline and follow-up data could be included. The mean empowerment score increased 0.1 on a 5 point scale in the overall intervention group, which was not significantly different from that of the control group (mean difference after adjusting for baseline 0.039, 95% confidence interval −0.056 to 0.134). Lipid regulating drug treatment was intensified in 25% of intervention and 12% of control participants with increased cholesterol levels, which did not reach significance when the intervention was compared with the usual care group (odds ratio 2.54, 95% confidence interval 0.89 to 7.23). Prespecified explorative analyses showed that this effect was significant for the printed version of the decision aid in comparison to usual care (3.90, 1.29 to 11.80). No relevant or significant changes were seen for other treatments. Conclusion We found no evidence that the patient oriented treatment decision aid improves patient empowerment by an important amount. The aid was not used to its full extent in a substantial number of participants. Trial registration Dutch trial register NTR1942.
Positive Transcription Elongation Factor b Activity in Compensatory Myocardial Hypertrophy is Regulated by Cardiac Lineage Protein-1
Authors: Jorge Espinoza-Derout, Michael Wagner, Louis Salciccioli, Jason M. Lazar, Sikha Bhaduri, Eduardo Mascareno, Brahim Chaqour, M.A.Q. Siddiqui
Journal: Circulation Research (2009)

Emerging evidence illustrates the importance of the positive transcription elongation factor (P-TEF)b in control of global RNA synthesis, which constitutes a major feature of the compensatory response to diverse hypertrophic stimuli in cardiomyocytes. P-TEFb complex, composed of cyclin T and cdk9, is critical for elongation of nascent RNA chains via phosphorylation of the carboxyl-terminal domain of RNA polymerase (Pol) II. We and others have shown that the activity of P-TEFb is inhibited by its association with cardiac lineage protein (CLP)-1, the mouse homolog of human HEXIM1, in various physiological and pathological conditions. To investigate the mechanism of control of P-TEFb activity by CLP-1 in cardiac hypertrophy, we used a transgenic mouse model of hypertrophy caused by overexpression of calcineurin in the heart. We observed that the level of CLP-1 associated with P-TEFb was reduced markedly in hypertrophic hearts. We also generated bigenic mice (MHC-cyclin T1/CLP-1(+/-)) by crossing MHC-cyclin T1 transgenic mice with CLP-1 heterozygote. The bigenic mice exhibit enhanced susceptibility to hypertrophy that is accompanied with an increase in cdk9 activity via an increase in serine 2 phosphorylation of carboxyl-terminal domain and an increase in GLUT1/GLUT4 ratio. These mice have compensated systolic function without evidence of fibrosis and reduced lifespan. These data suggest that the reduced level of CLP-1 introduced in the background of elevated levels of cyclin T1 elevates derepression of P-TEFb activity and emphasizes the importance of the role of CLP-1 in the mechanism governing compensatory hypertrophy in cardiomyocytes.
Cortical development: A progressive and selective mesh, with or without constructivism
Authors: Henry Kennedy, Colette Dehay
Journal: Behavioral and Brain Sciences (1997)

A credible account of the neurobiology underlying cognitive development cannot afford to ignore the recently demonstrated innate regionalisation of the neocortex as well as the ontogeny of corticocortical phenomena, only for the latter does the timing of development permit control by external events and this is most likely to occur at later stages in the fine tuning of cortical microcircuitry.
Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept
Authors: Rosalind H.E. Chong, Emilio Gonzalez-Gonzalez, Maria F. Lara, Tycho J. Speaker, Christopher H. Contag, Roger L. Kaspar, Sion A. Coulman, Rachel Hargest, James C. Birchall
Journal: Journal of Controlled Release (2013)
Clinical Value Of a Negative Skin Test To Contrast Radio Media (CR) In Further Exposures
Authors: Luiz C.G. Arcanjo, Tania M.T. Gonçalves, Flavia C. Loyola, Matheus Ribeiro, Alfredo Alves Neto, Tatiana L. Carvalho, Jose Luiz M. Rios
Journal: Journal of Allergy and Clinical Immunology (2014)
Renal Allotransplantation for Bilateral Renal Tumors
Authors: Peter R. Jochimsen
Journal: JAMA (1969)

A patient with tuberous sclerosis and renal failure secondary to bilateral multiple hamartomas and clear-cell tumors of the kidneys had renal allotransplantation performed. A second patient with the same syndrome has undergone nephrectomy for hamartomas of the right kidney and has a large tumor mass in the remaining kidney. This patient will have a renal transplant when her status requires. In spite of a systemic disorder, we consider these patients good candidates to have transplants. Clearcell renal cancers in patients with tuberous sclerosis do not appear to behave as malignancies and do not offer a contraindication to transplantation. Children with bilateral Wilm's tumors and individuals with bilateral clear-cell tumors of both kidneys or of a sole functioning kidney may also greatly benefit from having a renal transplant.
Apituitarism and the Anencephalic Syndrome
Authors: D. L. Barlow
Journal: BMJ (1923)

TABLE 11.-The Relative Value of Proprietary Foods and Milk as Sources of Vitamins.Amount of milk which Approxi-provides approximately mate the same quan Lity of Proprietary Weight Vitamin as is contained Propriery Adult Dose. of Total in the daJly adult dose Food.Daily of the proprietary foods.Adult Dose.Vitamin A. Vitamin B. Gram.Oz.Oz.Metagen Two to five 5-grain 1.6 1 1.5 capsules daily Maltoline...One tablespoonful 45 8 13 3 times a day Roboleine... Two teaspoonfuls 30 5.3 17 3 times a day Virol ... Two teaspoonfuls 30 11 17 3 times a day Vitmar ... Two teaspoonfuls 40 14 23 4 times a daycontent of a teaspoonful of cod-liver oil.The present paper is of course solely concerned with the vitamin content of these preparations, and no opinion is expressed concerning their merits in any other respect.Whilst these experiments were in progress two papers appeared in America describing similar investigations.Hess, Moore, and Calvin2 investigated the content in vitamin B and C of metagen and vitamon (mastin).They concluded that "metagen as obtained on the open market contains no demonstrable amount of antiscorbutic substance (vitamin C), as sliown by experiments on guinea-pigs."They also found that metagen contained less vitamin B than commercial yeast, as shown by its power to protect pigeons
Eliciting Patient Preferences
Authors: Richard D. Callahan
Journal: Annals of Internal Medicine (1993)

Letters1 January 1993Eliciting Patient PreferencesRichard D. Callahan, MDRichard D. Callahan, MDRegional Oncology & Hematology Associates; Suite G-102; 445 Biltmore Avenue; Asheville, NC 28801Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-1-199301010-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Levine and colleagues [1] have attempted to provide patients with unbiased information regarding the benefits and costs of adjuvant chemotherapy for breast cancer to allow patients to make personal choices. However, it may not be a totally rational decision. Unless one is practicing on the planet Vulcan, emotional factors are involved in decision making. Fifty-seven percent of the “healthy” volunteers opted for chemotherapy compared with 92% of the women actually threatened by breast cancer. Real fear and anxiety in patients who had just undergone surgery for breast cancer may well have motivated a greater number to elect ...REFERENCE1. Levine M, Gafni A, Markham B, MacFarlane D. A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med. 1992; 117:53-8. Google Scholar Author, Article, and Disclosure InformationAuthors: Richard D. Callahan, MDAffiliations: Regional Oncology & Hematology Associates; Suite G-102; 445 Biltmore Avenue; Asheville, NC 28801 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byShould patients have control over their own health care?: Empirical evidence and research issuesFraming of outcome and probability of recurrence: Breast cancer patients' choice of adjuvant chemotherapy (ACT) in hypothetical patient scenarios 1 January 1993Volume 118, Issue 1Page: 76-77KeywordsAdjuvant chemotherapyAnxietyBreast cancerCancer treatmentChemotherapyDecision makingEmotionsFearHearingSurgery ePublished: 15 August 2000 Issue Published: 1 January 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Benign cephalic histiocytosis: a case report
Authors: K.M. GODFREY, M.P. JAMES
Journal: British Journal of Dermatology (1990)

Journal Article Benign cephalic histiocytosis: a case report Get access K.M. GODFREY, K.M. GODFREY Royal Berkshire Hospital, London Road, Reading Search for other works by this author on: Oxford Academic Google Scholar M.P. JAMES M.P. JAMES Royal Berkshire Hospital, London Road, Reading Dr M.P.James, Royal Berkshire Hospital, London Road, Reading, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 123, Issue 2, 1 August 1990, Pages 245–248, https://doi.org/10.1111/j.1365-2133.1990.tb01854.x Published: 01 August 1990
Constrictive pericarditis, pyopericardium, and tamponade with rheumatoid arthritis.
Authors: A J Marshall, W C Brownlee, G Keen
Journal: Annals of the Rheumatic Diseases (1979)

Constrictive pericarditis and pyopericardium with tamponade in a patient and rheumatoid arthritis is described. No fever was recorded despite a litre of pus in the pericardial sac, perhaps because of previous treatment with hydrocortisone. Echocardiography is a diagnostic advance.
Defective inflammatory response in interleukin 6-deficient mice.
Authors: E Fattori, M Cappelletti, P Costa, C Sellitto, L Cantoni, M Carelli, R Faggioni, G Fantuzzi, P Ghezzi, V Poli
Journal: The Journal of Experimental Medicine (1994)

Systemic and localized inflammation elicit a number of host responses which include fever, cachexia, hypoglycemia, and major changes in the concentration of liver plasma proteins. Interleukin 6 (IL-6) is considered an important mediator of the inflammatory response, together with IL-1 and tumor necrosis factor alpha (TNF-alpha). The purpose of this study was to unequivocally determine the role of IL-6 in these phenomena making use of IL-6-deficient mice that we have recently generated by gene targeting. We report here that in the absence of IL-6, mice are unable to mount a normal inflammatory response to localized tissue damage generated by turpentine injection. The induction of acute phase proteins is dramatically reduced, mice do not lose body weight and only suffer from mild anorexia and hypoglycemia. In contrast, when systemic inflammation is elicited through the injection of bacterial lipopolysaccharide (LPS), these parameters are altered to the same extent both in wild-type and IL-6-deficient mice, demonstrating that under these conditions IL-6 function is dispensable. Moreover, we show that LPS-treated IL-6-deficient mice produce three times more TNF-alpha than wild-type controls, suggesting that increased TNF-alpha production might be one of the compensatory mechanisms through which a normal response to LPS is achieved in the absence of IL-6. We also show that corticosterone is normally induced in IL-6-deficient mice, demonstrating that IL-6 is not required for the activation of the hypothalamic-pituitary-adrenal axis. Our results reinforce the idea that different patterns of cytokines are involved in systemic and localized tissue damage, and identify IL-6 as an essential mediator of the inflammatory response to localized inflammation.
TCT-470 The Clinical Implication of Neointimal Characteristics Observed in Optical Coherence Tomography after Stent Implantation
Authors: Jung-Hee Lee, Jung-Sun Kim, Dong-Ho Shin, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong-Ki Hong
Journal: Journal of the American College of Cardiology (2013)
707 screening for advanced fibrosis using non-invasive biomarkers (Fibrotest Fibrosure) in diabetic patients
Authors: S. Jacqueminet, R. Morra, M. Munteanu, L. Devers, D. Messous, M. Bernard, S. Jeanne, C. Sachon, A. Heurtier, D. Rousselot, A. Mercadier, F. Imbert Bismut, V. Ratziu, A. Grimaldi, T. Poynard
Journal: Journal of Hepatology (2006)
Abstract 3559: Celastrol, a unique multifunctional pharmacophore with multiple targets as an effective therapeutic against ErbB2-overexpressing cancers
Authors: Srikumar M. Raja, Robert J. Clubb, Cesar Ortega-Cava, Lei Duan, Tameka A. Bailey, Vimla Band, Hamid Band
Journal: Cancer Research (2010)

Abstract Celastrol, a novel triterpene natural product, has shown immense promise against various cancer models including prostate cancer, pancreatic cancer, leukemia, and melanoma. A unique property of Celastrol is its ability to affect multiple oncogenic cellular targets that include the proteasome, HSP90, I Kappa B Kinase and the cellular redox-balance system. Celastrol could therefore be viewed as a multifunctional pharmacophore simultaneously affecting multiple targets within oncogenically transformed cell. In this paper we explore the properties of this unique pharmacophore as therapeutic agent for treating ErbB2-overexpressing breast cancers. Celastrol not only induced ubiquitinylation and degradation of ErbB2 and other HSP90 client proteins; it also increased cellular ROS levels, and killed ErbB2-overexpressing cells with higher selectivity. Comparison of IC50 values amongst a panel of breast cancer cell lines indicated a strong correlation of basal ROS-levels to sensitivity to killing. ErbB2-overexpression led to increase in basal ROS and consequently ErbB2-high cells were more sensitive to Celastrol than ErbB2-low cells. Celastrol also strongly synergized with ErbB2-targeted therapeutics, Trastuzumab and Lapatinib, resulting in enhanced ErbB2-specific cellular cytotoxicity at substantially reduced doses of Celastrol. Pharmacogenomic expression analysis comparing 17-AAG and Celastrol confirmed several common signatures and revealed unique signatures. Celastrol, but not 17-AAG, could potently induce depletion of Aurora A Kinase at both the transcript as well as protein level, adding to the spectrum of targets, given the importance of Aurora Kinase as a target in development of anti-cancer therapeutics. In vivo xenograft experiments using ErbB2-overexpressing breast cancer model confirmed the potential of Celastrol as a therapeutic agent for the treatment of ErbB2-overexpressing breast cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3559.
Phenylbutazone and Motor Neurone Disease
Authors: A. M. G. Campbell
Journal: BMJ (1964)

JORNAL 1 was found that the average number of E.C.T.s given in the course of a year follow- ing admission and the number of days in hospital in that year were both reduced in 1961.The figures are shown in the table.While other factors may have been oper- ating, I think that a major one in accounting for the change is that 22 of the 28 patients in 1961 were treated with imipramine.-Iam, etc.,
TREATMENT OF SHOCK WITH GLUCOSE INFUSIONS AND INSULIN
Authors: DAVID FISHER
Journal: JAMA (1924)

Shock or exhaustion may be produced by various causes, such as fear, worry, trauma, physical injury, toxins, infection, hemorrhage, excessive muscular exertion, starvation and insomnia. The exact mechanism or physicochemical changes taking place in the production of shock are unknown. The theories explaining this are legion, and need not be detailed here, except to mention briefly that the blame has been laid to capillary distention, dilatation of the splanchnic vessels, fat embolism and absorption of toxins from traumatized tissues. Whatever the cause or mechanism may be, the clinical pictures seem to be identical. When we consider the histologic pathology of shock, we are on a little firmer ground. The organs of the body especially involved in shock are the thyroid, suprarenals, brain, liver and muscles. This constitutes, figuratively speaking, our kinetic system, which contains potential energy delivered as a result of environmental stimuli. Crile1has shown histologically, working with
Three-Dimensional Electroanatomical Voltage Mapping and Histologic Evaluation of Myocardial Substrate in Right Ventricular Outflow Tract Tachycardia
Authors: Domenico Corrado, Cristina Basso, Loira Leoni, Barbara Tokajuk, Pietro Turrini, Barbara Bauce, Federico Migliore, Andrea Pavei, Giuseppe Tarantini, Massimo Napodano, Angelo Ramondo, Gianfranco Buja, Sabino Iliceto, Gaetano Thiene
Journal: Journal of the American College of Cardiology (2008)
503 Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (CHB)
Authors: T.T. Chang, M.L. Shiffman, M. Tong, Y.E. Liaw, P. Komolmit, J. Sorbel, S. Arterburn, E. Mondou, S. Chuck, P. Marcellin
Journal: Journal of Hepatology (2006)